On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively. Dr. Scheller's and Mr. Saunders' resignations were not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Mr. Saunders will also be stepping down as chair of the Compensation Committee of the Board when he resigns.

On February 23, 2023, the Company announced that Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has been appointed by the Board to serve as a director of the Company and fill the vacancy created by the resignation of Dr. Scheller. Effective as of February 21, 2023, the Board appointed Dr. McCormick to the Board to fill the vacancy created by Dr. Scheller's resignation.

Dr. McCormick will serve as a Class I director of the Company, to hold office until the date of the annual meeting of stockholders during the year ending December 31, 2023 or until his earlier death, resignation or removal. Dr. McCormick, age 72, currently also serves as the Company's Chairman of Oncology and has been in this position since April 2019. Dr. McCormick has held the positions of Director of the UCSF Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization, and served as Associate Dean of the UCSF School of Medicine from 1997 to 2014.

Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991, and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992, Dr. McCormick founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996, a member of the National Academy of Sciences since 2014 and has served as President, 2012 to 2013, for the American Association for Cancer Research.

Since 2013, Dr. McCormick has led the National Cancer Institute's Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund.